Navigation Links
Success of HIV may depend in its mutations

Researchers observe that one reason AIDS may progress as a disease is the human immunodeficiency virus mutates so rapidly within the human body that it confounds the already-weakened immune system's ability to defend against it. In addition, conventional tests used to determine how well a person// infected with HIV can mount an immune defense can be misleading, the researchers, from Harvard Medical School's Center for Blood Research, have found.

"The immune system needs to evolve along with the virus and this evolution becomes difficult because it is in a milieu of immune deficiency," researcher Premlata Shankar told United Press International. We overstate the immune response because the virus used to test a person's response has many regions to which an immune response has already been developed.

As reported in the November issue of the Journal of Clinical Investigation, although the immune system's memory-based component might continue to resist the strain of HIV it first encountered -- or strains used in laboratory tests -- subsequent viral mutations weaken its ability to mount an effective defense.

Although HIV's ability to mutate rapidly has been well documented, the effects of those mutations on an infected individual have not been studied thoroughly. So Shankar and colleagues examined the immune system's killer cell responses to mutated forms of HIV taken from infected people at different stages of their infection. They found the killer cells from patients with more advanced infections could not destroy the mutated virus, even though they still could neutralize common laboratory strains.

In contrast, killer cells from people with less-advanced HIV infections could destroy both the lab test strains and their own mutated forms. "The side-by-side comparison of cellular responses to laboratory strains and autologous (mutated after infection) strains at different disease stages is new," immunologist Beth Jamieson, w ith the David Geffen School of Medicine at the University of California, Los Angeles, told UPI. "This shows that the response to virus is lost later in infection. Now we need to know why," she said. "While there are no direct implications for diagnosis or treatment, an important motivation for this sort of study is the development of knowledge that could lead to successful HIV vaccines, both to prevent and to treat HIV infection," infectious disease specialist Stuart Ray, of the Johns Hopkins University School of Medicine in Baltimore, told UPI. When a person is first infected with HIV, his or her immune system responds by producing killer T-cells, called CD8- T, and CD4-T helper cells. The system also remembers the type of molecules on the surface of the attacking virus, so the next time the system encounters the virus, it produces many cells from memory to attack it again. But when the virus mutates, the immune system is no longer able to identify and kill the mutations.

The researchers found much of the deficiency also occurs because HIV destroys the helper cells. This stops the efficient production of new killer cells and it helps to weaken the killer cells that are produced. Because of this finding, Jamieson recommended further research "looking at the epitopes (surface proteins) on the virus over time in individuals."


'"/>




Related medicine news :

1. Plastic Sling Has Proved Successful In Improving Aging Of The Neck
2. Does Success in School Differ From the Real World Success ?
3. The Success Rate Of Angioplasty In Female Patients Low
4. Success Of Preventable High-Risk HPV Infections With Vaccines May Vary
5. Successful creation of human embryos from a single parent for the first time
6. Fertility Treatment Offered During Summer Has Better Chances For Success
7. Happiness Plays An Important Role In Success
8. French Doctors Successfully Separate Twins Joined At Spine
9. Alzheimer’s disease trial With EVT 101 For Successfully Complete
10. Switching Off Protein Could Play Key Role In Success Of Radiation Therapy For Cancer
11. Overweight Briton Underwent Successful Surgery In India Being Denied By NHS
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/22/2017)... Peoria, IL (PRWEB) , ... May 22, 2017 ... ... HealthCare, is part of a larger group investing in InsightRX, an early stage ... a patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund ...
(Date:5/21/2017)... FL (PRWEB) , ... May 20, 2017 , ... Pot. ... it, find it, review it, and share its attributes like never before. More than ... directory to connect cannabis enthusiasts to stores, strains, products – and for the first ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... longer than six months since you've seen a dentist, it's time for a ... and getting x-rays once per year. , Dental checkups are a relatively easy ...
(Date:5/19/2017)... ... May 19, 2017 , ... Springfield, Vermont-based law firm ... Titled " Ten Good Reasons To Hire An Experienced Personal Injury Attorney, " the ... an accident or injury. As the article says. if someone is injured due ...
(Date:5/19/2017)... ... 19, 2017 , ... As a groundbreaking surgeon on the frontline of prostate ... screenings. Early detection of the disease, he says, can make a world of difference. ... , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: